EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects

Mario Detomas, Timo Deutschbein, Barbara Altieri

Experimental and Clinical Endocrinology & Diabetes · 2024-12 · 132 (12) · 723-731

DOI: 10.1055/a-2317-0801 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, online erschienen am 14.06.2024. Verfasst von Mario Detomas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Cushing Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Clinician Scientist program RISE funded by the Else-Kröner-Fresenius-Stiftung & the Eva-Luise–und-Horst-Köhler Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endogenous Cushing’s syndrome (CS) is a rare disease characterized by a glucocorticoid excess. If inadequately treated, hypercortisolism can lead to increased morbidity and mortality. Surgical removal of the underlying tumor is the first-line treatment but is sometimes not feasible or even contraindicated. Additionally, in cases with severe CS, rapid control of hypercortisolism may be required. In these scenarios, steroidogenesis inhibitors represent a therapeutic alternative to surgery. Over the last years, the knowledge of the broad therapeutic effects of steroidogenesis inhibitors per se and the number of available drugs have increased. However, large comparative studies are still lacking. Accordingly, the decision on which drug to be used in a certain patient or clinical setting may be difficult. This review aims to summarize the main characteristics of steroidogenesis inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cushing SyndromeHumansSteroid Synthesis Inhibitors

Substanzen

Steroid Synthesis Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
  • Medicover Oldenburg MVZ, Oldenburg, Germany.

Förderung

  • Clinician Scientist program RISE funded by the Else-Kröner-Fresenius-Stiftung & the Eva-Luise–und-Horst-Köhler Stiftung

Zitieren

APA

Detomas, M., Deutschbein, T., & Altieri, B. (2024). Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects. Experimental and Clinical Endocrinology & Diabetes, 132(12), 723-731. https://doi.org/10.1055/a-2317-0801

Vancouver

Detomas M, Deutschbein T, Altieri B. Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects. Experimental and Clinical Endocrinology & Diabetes. 2024;132(12):723-731. doi:10.1055/a-2317-0801

BibTeX
@article{Detomas2024,
  author = {Detomas, Mario and Deutschbein, Timo and Altieri, Barbara},
  title = {Medical Therapy of Endogenous Cushing’s Syndrome with Steroidogenesis Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic Effects},
  journal = {Experimental and Clinical Endocrinology & Diabetes},
  year = {2024},
  volume = {132},
  number = {12},
  pages = {723--731},
  doi = {10.1055/a-2317-0801}
}
Kostenlos starten →